Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05339633 · ClinicalTrials.gov registry record · Phase 1
Study in Healthy Adult Female Subjects
A Phase 1 study, sponsored by InventisBio Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05339633: Completed Phase 1 study, sponsored by InventisBio Co..
NCT05339633 is a Phase 1 study that has completed, run by InventisBio Co.. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05339633, a Phase 1 study, has completed, sponsored by InventisBio Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
An Open Label Phase 1 Study in Healthy Adult Female Subjects to Determine the Mass Balance Recovery, Absorption, Metabolism, and Excretion of \[14C\] D-0502 Following Single Oral Dose Administration
Primary Outcome
To assess the mass balance (i.e., cumulative excretion in urine and feces) of D 0502 and the percentages of radiolabel recovered in urine and feces following administration of a single oral dose of D-0502/5 microcuries (µCi) \[14C\] D-0502 in healthy, adult female subjects
Interventions
- DRUG [14C]-D-0502
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2022-10-31 |
| Phase | Phase 1 |
What the finished NCT05339633 record still lists
NCT05339633 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which [14C]-D-0502 is the first listed.
NCT05339633 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05339633 about?
NCT05339633 is a clinical study titled "Study in Healthy Adult Female Subjects". An Open Label Phase 1 Study in Healthy Adult Female Subjects to Determine the Mass Balance Recovery, Absorption, Metabolism, and Excretion of \[14C\] D-0502 Following Single Oral Dose Administration
What is the current status of trial NCT05339633?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2022-03-29. Estimated completion is 2022-10-31.
What interventions are being tested in trial NCT05339633?
The interventions under investigation include: [14C]-D-0502 (DRUG).
Who is sponsoring clinical trial NCT05339633?
This trial is sponsored by InventisBio Co., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05339633's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI